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Research
Lead is ubiquitous in the environment and 
has been associated with cardiovascular mor-
tality (Lustberg and Silbergeld 2002; Menke 
et al. 2006; Schober et al. 2006; Weisskopf 
et al. 2009) and cardiovascular disease (Navas-
Acien et al. 2007), which is the leading cause 
of death worldwide (Lopez et al. 2006) and 
accounts for 26% of total deaths in the United 
States (Heron et al. 2009). One possible 
mechanism for these cardiovascular effects 
of lead is electrocardiographic conduction 
abnormalities that have been shown to predict 
future cardiovascular disease and mortality 
(Chugh et al. 2009; Dekker et al. 2004).
Cross-sectional studies among highly 
exposed workers have explored associations 
between lead exposure and electrocardio-
graphic conduction abnormalities, although 
with somewhat inconsistent results (Kopp et al. 
1988). Only one previous study has explored 
these associations among people exposed at 
general environment levels well below those 
seen in occupational settings (Cheng et al. 
1998). That study among participants in the 
Normative Aging Study (NAS) of the U.S. 
Department of Veterans Affairs (VA) found an 
association of cumulative lead exposure with 
higher heart rate–corrected QT (QTc) interval 
and heart rate–corrected QRS (QRSc) dura-
tion, and with higher risk of intraventricular 
conduction defect (IVCD), but only among 
men < 65 years of age. That study, however, 
considered lead exposure and conduction 
abnormalities measured at the same time and 
therefore had to include people with existing 
conduction deficits. No prospective follow-up 
study has been performed to assess the asso-
ciation of lead exposure with change in these 
parameters over time among those participants 
who were free of disturbances at baseline. 
In the present study, we investigated the 
potential association between lead exposure 
biomarkers at baseline and future QT prolon-
gation, IVCD, and atrioventricular conduc-
tion defect (AVCD), as well as changes over 
time in the QTc and heart rate–  corrected JT 
(JTc) intervals and in QRSc duration among 
the same participants in the NAS as the previ-
ous report of findings.
Materials and Methods
Study population. This prospective cohort 
study was conducted within a subgroup of 
the NAS, a cohort study of aging established 
by the U.S. Veterans Administration (VA) in 
1963. The VA recruited 2,280 men who were 
living in the Greater Boston area who were 
free of known chronic medical conditions 
such as heart disease, hypertension, diabetes 
mellitus, cancer, peptic ulcer, gout, recurrent 
asthma, bronchitis, and sinusitis (Bell et al. 
1966). The details on the cohort, as well as 
the subgroup in which bone lead levels were 
measured, have been described elsewhere 
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Ba c k g r o u n d: No studies have examined the association between cumulative low-level lead expo-
sure and the prospective development of electrocardiographic conduction abnormalities, which may 
mediate the association between lead and several cardiovascular end points.
oB j e c t i v e: We prospectively examined the association between lead exposure and the development 
of electrocardiographic conduction abnormalities.
Me t h o d s : We assessed blood lead, bone lead—a biomarker of cumulative lead exposure— 
measured with K-shell X-ray fluorescence, and electrocardiographic end points among 600 men in 
the Normative Aging Study who were free of electrocardiographic abnormalities at the time of the 
baseline ECG. Of these men, we had follow-up data from a second electrocardiogram for 496 men 
8.1 (SD = 3.1) years later, on average. We used repeated measures linear regression to analyze 
change in electrocardiographic conduction timing and logistic regression to estimate odds ratios 
(ORs) and 95% confidence intervals (CIs) for developing specific conduction disturbances and 
adjusted for potential confounders.
re s u l t s: Mean (± SD) blood (5.8 ± 3.6), patella bone (30.3 ± 17.7), and tibia bone (21.6 ± 12.0) 
lead concentrations were similar to those found in samples from the general U.S. population and 
much lower than those reported in occupationally exposed groups. Compared with those in the 
lowest tertile of tibia lead, those in the highest had a 7.94-ms (95% CI, 1.42–14.45) increase in 
heart rate–corrected QT (QTc) interval and a 5.94-ms increase in heart rate–corrected QRS (95% 
CI, 1.66–10.22) duration > 8 years. Those in the highest tertile of tibia lead also had increased odds 
of QT prolongation (QTc ≥ 440 msec; OR = 2.53; 95% CI, 1.22–5.25) and JT prolongation (heart 
rate–corrected JT > 360 msec; OR = 2.53; 95% CI, 0.93–6.91). Results were weaker for patella 
lead. No associations were identified with blood lead.
co n c l u s i o n s: This study suggests that low-level cumulative exposure to lead is associated with worse 
future cardiac conductivity in the ventricular myocardium, as reflected in QT interval characteristics.
key w o r d s : ECG, electrocardiographic conduction, environmental exposure, epidemiology, lead, 
prospective study. Environ Health Perspect 119:940–944 (2011).  doi:10.1289/ehp.1003279 
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(Hu et al. 1998). Briefly, since 1963, NAS 
participants have come to the VA Boston 
Healthcare system, Jamaica Plain division, 
Boston, Massachusetts, for clinical examina-
tion every 3–5 years. At each visit, they also 
completed extensive health- and lifestyle-
related questionnaires. The annual attrition 
rate for all reasons has been < 1%, and the 
response rate to questionnaires mailed as sup-
plements to on-site clinical examinations has 
been > 80%. Beginning in 1991, bone lead 
measurements were initiated among NAS par-
ticipants who expressed interest and who gave 
informed consent. Of the 1,349 participants 
who were seen for their regularly scheduled 
visits, 788 had bone lead measurements taken 
and blood specimens were obtained from the 
participants—these blood samples were used 
to determine lead levels. Blood lead levels and 
other characteristics that included age, race, 
education, smoking status, alcohol intake, 
body mass index (BMI), diagnosed hyper-
tension, fasting blood glucose levels, diabetes 
mellitus, and serum cholesterol levels, were 
not substantially different between those NAS 
men who did and did not participate in the 
bone lead study (Cheng et al. 1998).
Among subjects with bone lead measure-
ments, 775 had electrocardiogram (ECG) 
measurements made at their regular VA visits 
between 1989 and 1996 (baseline). Of these 
men, we excluded 175 because 151 had the 
electrocardiographic conduction disturbances 
VCD, AVCD, or arrhythmia; 12 had missing 
QTc interval; and 12 were missing potential 
confounders (e.g., education, smoking status, 
BMI, serum calcium, or diabetes mellitus). 
A total of 600 subjects remained. We also 
excluded participants with high uncertainty 
values for tibia (n = 6) and patella (n = 1) 
lead measurements (see “Bone lead and blood 
lead measurement” below) and 11 individuals 
who had no blood lead measurement. The fol-
lowing number of participants were included 
in the analyses: 599 for patella lead, 594 for 
tibia lead, and 589 for blood lead. We had a 
follow-up ECG for 496 (82.8%) of the 599 
men with patella lead data, 491 (82.7%) of 
the 594 with tibia lead data, and 488 (82.9%) 
of the 589 men with blood lead data.
The present study was approved by the 
Human Subjects Committees of the VA 
Boston Healthcare System, the Brigham and 
Women’s Hospital, and the Harvard School 
of Public Health; all participants provided 
informed consent.
Bone lead and blood lead measurement. 
The lead contents in midtibia shaft and patella 
bone were measured noninvasively via K-shell 
X-ray fluorescence (KXRF; ABIOMED, 
Danvers, MA, USA) as described previously 
(Hu et al. 1998). The physical principles, tech-
nical specifications, and validity of the mea-
surement also have been described elsewhere 
(Aro et al. 1994). The tibia shaft has been 
targeted for chronic lead exposure assessment 
because it is composed mostly of cortical bone 
in which the half-life of lead is on the order of 
decades. The patella consists mostly of trabecu-
lar bone, in which lead turnover is faster than 
in cortical bone—a half-life of about 8 years 
in men (Kim et al. 1997). The KXRF instru-
ment generates an unbiased point estimate of 
bone lead levels, accompanied by uncertainty 
estimates for each sample that are equivalent 
to the SD around the measurement. Negative 
estimates of bone lead may be generated when 
the true lead level is close to zero because of 
fluctuations in measurement. Using all point 
estimates, including negative values without 
detection limits, reduces bias in epidemiologic 
studies of bone lead (Kim et al. 1995). The 
average uncertainty of our KXRF bone lead 
measurement, equivalent to 1 SD, is approxi-
mately 5 µg/g. Lead measurements with high 
uncertainty values, > 10 µg/g for tibia and > 15 
µg/g for patella, were excluded because such 
values generally reflect excessive movement of 
a participant during measurement. Blood sam-
ples were taken in trace metal-free tubes that 
contained EDTA, and blood lead levels were 
analyzed using Zeeman background-corrected 
flameless atomic absorption spectroscopy 
(ESA Laboratories, Inc., Chelmsford, MA) 
with graphite furnace. The instrument was 
calibrated using National Bureau of Standards 
blood lead standards materials before sample 
measurement. For internal reliability, 10% of 
the samples were run in duplicate, 10% were 
controls, and 10% were blanks. We found no 
evidence of external contamination or signifi-
cant problems with reliability. To assess the 
external validity, we analyzed reference sam-
ples from the Centers for Disease Control and 
Prevention, Atlanta, Georgia; the coefficient of 
variation was 8% for samples < 30 µg/dL. The 
detection limit for blood lead was 1 µg/dL.
Electrocardiographic conduction dis-
turbances. A standard 12-lead resting-state 
ECG was performed at baseline and at regular 
follow-up visits over an average of 8 years. 
Results were sent to the Minnesota ECG 
Coding Center where ECG abnormalities 
were classified according to the Minnesota 
code (MC) categories (Prineas et al. 1982). We 
used the definitions of electrocardiographic 
conduction disturbances that were described 
in Cheng et al. (1998): IVCD (MC, 7-1-1, 
7-2-1, 7-4), AVCD (MC, 6-3, 6-2-x, 6-1), 
and other arrhythmias (MC, 8-1-1, 8-1-2, 
8-1-3, 8-3-x, 6-4-x). Heart rate correction for 
QTc intervals and QRSc durations were cal-
culated by Bazett’s formula (Ahnve 1985). The 
JTc interval was calculated by subtracting the 
QRS duration from the QTc interval (Crow 
et al. 2003). Prolongations of the QTc and 
the JTc intervals were defined as ≥ 440 msec 
(Montanez et al. 2004) and > 360 msec 
(Piotrowicz et al. 2007), respectively. Straus 
et al. (2006) suggested an alternative abnormal 
QT prolongation cutoff of QTc > 450 msec 
for men; we also used this cutoff in our sensi-
tivity analyses.
Data analyses. Lead exposures at baseline 
were categorized into tertiles. To assess the lin-
ear trend in associations, we fit models using 
a term created by assigning to each individual 
the median value of his lead biomarker ter-
tile. To assess the prospective change in QTc 
and JTc intervals and QRSc duration from 
the baseline ECG to the follow-up ECG, we 
conducted repeated measurement analyses with 
random intercepts using an unstructured cova-
riance matrix to reflect correlation in repeated 
measurements of an individual subject. These 
models allow participants without a follow-up 
ECG measurement to be included, which helps 
improve precision of the estimates, even those 
for change over time. The model included a 
main effect term for bone lead as well as an 
interaction term between bone lead tertiles and 
number of years between ECG measurements. 
This interaction term estimates the association 
between lead exposure and change in ECG 
characteristics over time, which are the results 
we present. For the case–control analyses of 
the association between lead biomarkers and 
the dichotomous outcomes at the follow-up 
ECG of prolongation of QTc and JTc inter-
vals, AV block, IVCD, and arrhythmia, we 
estimated odds ratios (ORs) using logistic 
regression. These analyses were also among 
men free of conduction disturbances at base-
line, but by necessity included only those men 
with data from a second ECG measurement. 
Interquartile ranges (IQRs) are the difference 
between 25th and 75th percentiles. We con-
trolled for potential confounders including age 
(years), age squared, education (≤ high school, 
some college, college graduate, or graduate 
school), BMI (kilograms per square meter), 
smoking status (never, former, or current, 
and pack-years), diabetes status (yes/no), and 
albumin-adjusted serum calcium (milligrams 
per deciliter) at baseline. We also controlled 
for years between ECG tests and medications 
at the time of ECG measurement that could 
prolong the QT interval or induce torsades 
de points ventricular arrhythmia (Benoit 
et al. 2005; Chugh et al. 2009), including 
β-blockers. To identify QT-prolonging medi-
cations, we used these drugs grouped by risk of 
torsades and possible risk of torsades from the 
Arizona Center for Education and Research 
on Therapeutics (2010). We defined diabetes 
as physician’s diagnosis, use of diabetes med-
ication, or fasting glucose of ≥ 126 mg/dL. 
Lead has been found to be associated with 
hypertension (Navas-Acien et al. 2007) and 
high-density lipoprotein cholesterol (HDL-C) 
(Kristal-Boneh et al. 1999), which may act as 
intermediate variables on the causal pathway Eum et al.
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between lead and conduction disturbances. 
Therefore, we did not include hypertension 
or HDL-C in our primary analyses. Results 
were similar to the main analyses, however, 
when we additionally adjusted for hyperten-
sion (defined as physician’s diagnosis, sys-
tolic blood pressure ≥140 mmHg or diastolic 
blood pressure ≥ 90 mmHg) at baseline or 
HDL-C. We also examined models with the 
additional covariates physical activity (meta-
bolic equivalents), dietary intake of n-3 fatty 
acids (grams per day), and alcohol consump-
tion (≥ 2 drinks/day) and found similar results. 
We used SAS (version 9.2; SAS Institute Inc., 
Cary, NC) to perform all analyses. We defined 
statistical significance as p < 0.05.
Results
The distribution of lead exposure biomarkers 
by general characteristics of participants at 
baseline is shown in Table 1. The age (mean 
± SD) at the first ECG was 66.7 ± 7.0 years, 
with an average of 8.1 ± 3.1 years between 
the two ECGs. The mean ± SD tibia, patella, 
and blood lead levels at baseline were 21.6 
± 12.0 µg/g, 30.3 ± 17.7 µg/g, and 5.8 ± 3.6 
µg/dL, respectively, and the medians were 19 
(IQR, 13.5–27) µg/g, 27 (IQR, 18–37) µg/g, 
and 5 (IQR, 3.9–7.0) µg/dL, respectively. As 
expected, tibia and patella lead levels increased 
with age and lower education levels. Tibia lead 
correlated highly with patella lead (Spearman 
correlation coefficient = 0.62), and both tibia 
and patella lead correlated moderately with 
blood lead (Spearman correlation coefficients: 
tibia = 0.29; patella = 0.34). Those subjects for 
whom we had data from a second ECG meas-
urement (n = 496) did not differ in age-ad-
justed levels of tibia (mean = 21.2 µg/g), patella 
(mean = 29.8 µg/g), or blood lead (mean = 5.8 
µg/dL) or baseline QTc interval (mean = 394.0 
msec) from subjects without a second ECG 
(n = 103; means: tibia, 23.7 µg/g; patella, 32.4 
µg/g; blood, 5.9 µg/dL; baseline QTc interval, 
400.5 msec; all p-values for differences > 0.18).
Higher tibia lead was associated with signi-
fi  cant increases in QTc interval and QRSc 
duration (Table 2). Compared with those in 
the lowest tertile of tibia lead, participants 
in the highest tertile had a 7.94 msec [95% 
confidence interval (CI), 1.42–14.45; 
p-trend = 0.03] greater increase in QTc interval 
and a 5.94 msec (95% CI, 1.66–10.22; p-trend 
= 0.005) greater increase in QRSc duration 
over 8 years after adjusting for covariates. There 
was no association with patella or blood lead.
In analyses of ECG conductance distur-
bances at the follow-up ECG, higher baseline 
tibia lead was associated with the develop-
ment of QT prolongation and JT prolonga-
tion (Table 3). Compared with those in the 
lowest tertile of tibia lead, those in the high-
est had an OR of 2.53 (95% CI, 1.22–5.25; 
p-trend = 0.003) for the development of QT 
prolongation and 2.53 (95% CI, 0.93–6.91; 
p-trend = 0.04) for the development of JT 
prolongation, after adjusting for covariates. 
There was a paradoxical reduction in odds 
for AV block with higher baseline tibia and 
patella lead, but no association otherwise with 
patella or blood lead.
The results were not materially affected 
by excluding the 102 men who were tak-
ing QT-prolongation drugs at baseline, nor 
by including the one (patella) or six (tibia) 
men with high bone lead uncertainty values 
(data not shown). When we used the alterna-
tive definition for QT prolongation (QTc 
> 450 msec), a stronger estimated effect of 
tibia lead on QT prolongation was seen: The 
odds of QT prolongation for those in the 
highest tertile compared with the lowest tertile 
of tibia lead was 3.65 (95% CI, 1.43–9.31; 
p-trend = 0.004). In sensitivity analyses only 
among men who were nonhypertensive at 
baseline, we found similar association between 
tibia and patella lead and QTc interval, JTc 
intervals, QRSc duration, and QT and JT 
prolongations (data not shown). The only 
slight difference in results was elevated odds 
of arrhythmia for those in the highest ter-
tile of tibia lead compared with those in the 
lowest (OR = 2.01; 95% CI, 0.70–5.77; 
p-trend = 0.09).
Discussion
In this nonoccupational cohort of elderly 
men free of cardiac conduction abnormali-
ties at baseline, we found strong associa-
tions between long-term cumulative lead 
exposure, as measured by lead in tibia bone, 
and develop  ment of ECG conduction dis-
turbances. Over an average follow-up of 
approximately 8 years, higher tibia bone lead 
concentration at baseline was associated with 
greater increase over time in QTc interval and 
QRSc duration. Additionally, compared with 
those in the lowest tertile of tibia bone lead 
concentration, those in the highest tertile had 
significantly higher odds of developing QT 
and JT prolongation. It is unclear why there 
was an inverse association between bone lead 
and AVCD. Although chance cannot be ruled 
out, it is possible that survival bias contributes 
to this finding. We have previously found a 
strong association between patella bone lead 
and cardiovascular mortality (Weisskopf et al. 
2009), which could exert a downward influ-
ence on the effect estimates found here, pos-
sibly leading to the inverse association with 
AVCD. The association with mortality was 
weaker for tibia bone lead, thus a downward 
Table 1. Mean ± SD levels of lead exposure biomarkers by general characteristics at baseline.
Baseline characteristic n
Tibia lead 
(µg/g) n
Patella lead 
(µg/g) n
Blood lead 
(µg/dL)
Age (years)
< 60 96 15.0 ± 8.4 96 22.4 ± 11.9 95 5.2 ± 2.9
60–64 140 19.2 ± 9.1 142 26.0 ± 12.9 139 6.1 ± 4.4
65–69 175 22.5 ± 12.8 175 31.5 ± 17.5 170 6.2 ± 3.5
≥ 70 183 26.0 ± 12.8 186 36.3 ± 21.0 185 5.7 ± 3.3
BMI (kg/m2)
< 25 134 21.0 ± 9.4 133 28.9 ± 14.6 132 5.5 ± 3.7
25–29 313 22.0 ± 12.3 315 31.1 ± 18.5 310 6.0 ± 3.6
≥ 30 147 21.2 ± 13.5 151 29.6 ± 18.5 147 5.9 ± 3.4
Education (years)
≤ 12 (≤ high school) 61 28.2 ± 18.9 63 38.0 ± 20.8 62 6.2 ± 3.7
13–15 (some college) 213 22.6 ± 11.5 214 33.0 ± 19.2 211 6.1 ± 3.5
16 (college graduate) 252 20.6 ± 10.3 255 27.5 ± 15.8 249 5.6 ± 3.3
> 16 (graduate school) 68 16.4 ± 8.1 67 24.6 ± 12.2 67 5.6 ± 4.5
Albumin-adjusted serum calcium tertiles (mg/dL)
8.38–9.31 204 20.1 ± 12.0 206 27.8 ± 17.2 201 5.4 ± 2.9
9.32–9.58 188 21.9 ± 11.6 190 30.2 ± 17.6 191 5.9 ± 4.0
9.61–10.82 202 22.9 ± 12.2 203 32.8 ± 18.0 197 6.2 ± 3.7
Smoking status
Never 175 20.3 ± 11.2 175 28.5 ± 17.7 174 5.8 ± 3.4
Former 368 22.2 ± 12.5 372 31.0 ± 18.2 364 5.7 ± 3.5
Current 51 21.6 ± 10.6 52 30.7 ± 13.2 51 7.0 ± 4.5
QT prolongation medication
Yes 100 21.9 ± 12.5 102 29.7 ± 15.1 100 6.0 ± 3.5
No 494 21.5 ± 11.9 497 30.4 ± 18.2 489 5.8 ± 3.6
Diabetes
Yes 73 23.0 ± 11.1 74 32.7 ± 17.7 72 5.2 ± 3.0
No 521 21.4 ± 12.1 525 29.9 ± 17.7 517 5.9 ± 3.6
Hypertension
Yes 328 22.6 ± 13.0 329 31.3 ± 18.4 325 5.8 ± 3.3
No 266 20.4 ± 10.5 270 29.0 ± 16.7 264 5.9 ± 3.9
Myocardial infarction
Yes 35 21.5 ± 8.3 36 31.0 ± 16.8 35 6.7 ± 3.8
No 559 21.6 ± 12.2 563 30.2 ± 17.8 554 5.8 ± 3.6Cumulative lead exposure and cardiac conductivity
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influence on the associations reported here 
between tibia lead and ECG characteristics is 
less likely; however, were it to be present, it 
would suggest that the adverse associations we 
found would be underestimates. These asso-
ciations were observed among men with rela-
tively low blood and bone lead concentrations 
that were similar to other general population 
samples of similar age and much lower than 
the levels found among people occupation-
ally exposed to lead (Navas-Acien et al. 2008; 
Shih et al. 2007).
Several studies conducted in high-exposure 
settings have reported evidence of an effect of 
lead exposure on cardiac conduction times. 
Among 30 children with lead poisoning (range 
of blood lead concentration of 60–200 µg/dL), 
15 (50%) had prolongation of QTc interval 
(> QTc 420), which recovered to normal range 
after chelation therapy (Silver and Rodriguez-
Torres 1968). These results suggest that acute 
changes in blood lead levels can affect cardiac 
conduction parameters. In contrast, our cur-
rent results suggest effects of long-term cumu-
lative lead exposure rather than short-term 
effects. This difference is likely related to the 
fact that the finding of acute effects was among 
children and at exposure levels far higher than 
those in our study. In occupational settings, 
highly lead-exposed workers have been found 
to have increased QT interval, QRS duration, 
P-Q interval, and S-T segment compared with 
less exposed groups, although whether these 
effects are related to acute or more long-term 
lead exposures is not clear (Navas-Acien et al. 
2007). A previous cross-sectional study of 
NAS participants reported positive associa-
tions between tibia lead level and QTc inter-
val, QRSc duration, and odds for IVCD, but 
only among men < 65 years of age (Cheng 
et al. 1998). In contrast with our study, nei-
ther tibia nor patella lead levels were associated 
with QT prolongation in any age group. These 
limited findings may have reflected limitations 
of the study design, specifically, the simultane-
ous measurement of the exposures and out-
comes and inclusion of participants with ECG 
abnormalities in the analyses.
There are several mechanisms through 
which exposure to lead could induce cardiac 
conductivity disturbances in the ventricles. Lead 
exposure is associated with hypertension and 
several markers of increased cardiac afterload 
and hypertrophy, including increased ventricu-
lar mass and decreased ejection fraction and 
stroke volume (Gump et al. 2005; Kasperczyk 
et al. 2005; Navas-Acien et al. 2007; Schwartz 
1991). Ventricular hypertrophy is a known risk 
factor for QT prolongation and altered ven-
tricular conduction and repolarization (Ben-
David et al. 1992; Kang 2006; Kowey et al. 
1991). Thus, chronic lead exposure may give 
rise to disturbances in ventricular conduc-
tion and result in QT prolongation, through 
cardiac afterload, via lead-induced elevation 
in vascular resistance. This is also suggested by 
the only other study of lower exposure levels, a 
cross-sectional study that found a significantly 
increased prevalence of left ventricular hyper-
trophy associated with increased blood lead 
concentration among U.S. adults (Schwartz 
1991). Lead may also lead to ischemic myocar-
dial dysfunction. Many observational studies 
in workers (Gatagonova 1995a, 1995b, 1995c; 
Krotkiewski et al. 1964; Shcherbak 1988; 
Sroczynski et al. 1985) and in the general popu-
lation (Jain et al. 2007; Weisskopf et al. 2009) 
have found associations of lead exposure with 
ischemic cardiac end points. Coronary artery 
disease and myocardial ischemia can also lead 
to ventricular hypertrophy and disturbances in 
conductivity (Rubulis et al. 2006; Vrtovec et al. 
2005). Lead is also a well-known neuro  toxicant 
(Lidsky and Schneider 2003) and may induce 
ECG conduction abnormalities via adverse 
effects on the control of the heart by the auto-
nomic nervous system.
The particular strength of this study is 
the prospective cohort study design, with an 
8 year average follow-up of men who were free 
of ECG conductivity abnormalities at base-
line. However, several limitations existed in 
our analysis. Although the prospective design 
helps minimize many forms of bias, and we 
Table 3. ORs (95% CIs)a of incident abnormal cardiac conductivity at follow-up ECG by lead biomarker 
concentration at baseline among participants free of IVCD, AVCD, and arrhythmia at baseline ECG.
Lead biomarker level
QT 
prolongationb 
OR (95% CI)
JT 
prolongationc 
OR (95% CI)
IVCDd  
OR (95% CI)
AVCDe  
OR (95% CI)
Arrhythmiaf  
OR (95% CI)
Tibia lead tertile (µg/g)
Case/control 67/387 32/425 33/458 25/466 92/399
< 16 Reference Reference Reference Reference Reference
16.0–23 0.86 (0.39–1.88) 0.93 (0.32–2.72) 1.46 (0.56–3.85) 0.77 (0.29–2.09) 0.53 (0.28–1.01)
> 23 2.53 (1.22–5.25) 2.53 (0.93–6.91) 1.45 (0.52–4.08) 0.23 (0.06–0.87) 1.18 (0.64–2.16)
p for trend test 0.003 0.04 0.55 0.03 0.32
Patella lead tertile (µg/g)
Case/control 68/391 32/429 33/463 26/470 96/400
< 22 Reference Reference Reference Reference Reference
22–33 2.67 (1.28–5.56) 2.24 (0.81–6.20) 3.77 (1.37–10.33) 0.49 (0.18–1.31) 1.06 (0.59–1.91)
> 33 2.10 (0.96–4.60) 2.18 (0.75–6.35) 1.57 (0.49–5.00) 0.19 (0.05–0.68) 1.09 (0.59–2.02)
p for trend test 0.14 0.21 0.75 0.01 0.78
Blood lead tertile (µg/dL)
Case/control 68/383 32/421 31/457 25/463 94/394
< 4 Reference Reference Reference Reference Reference
4–6 1.19 (0.60–2.37) 0.94 (0.38–2.34) 0.59 (0.20–1.81) 0.44 (0.13–1.47) 1.42 (0.80–2.51)
> 6 1.31 (0.69–2.48) 0.66 (0.26–1.67) 1.27 (0.54–3.02) 0.52 (0.19–1.45) 0.85 (0.48–1.52)
p for trend test 0.41 0.40 0.65 0.16 0.75
aAdjusted for age (years) and age squared, education (≤ high school, some college, college graduate, or graduate 
school), smoking (never, former, or current and pack-years), body mass index (kg/m2), albumin-adjusted serum calcium 
(mg/dL), and diabetes status (yes/no) at baseline, as well as years between ECG tests and QT-prolongation drugs (yes/
no) at the time of ECG measurement. bHeart rate–corrected QT interval of ≥ 440 msec; 37 participants with QT prolonga-
tion at baseline were excluded. cHeart rate–corrected JT interval of ≥ 360 msec; 34 participants with JT prolongation at 
baseline were excluded. dDefined MCs including 7-1-1, 7-2-1, 7-4. eDefined MCs including 6-3, 6-2-x, 6-1. fDefined MCs 
including 8-1-1, 8-1-2, 8-1-3, 8-3-x, 6-4-x.
Table 2. Adjusted 8-year change (95% CI) in QTc interval, QRSc duration, and JTc intervala from baseline 
to follow-up ECG examination, by lead biomarker concentration at baseline, among participants who 
were free of IVCD, AVCD, and arrhythmia at baseline ECG.
Lead biomarker level n QTc QRSc JTc
Tibia lead tertile (µg/g)
< 16 191 Reference Reference Reference
16.0–23 208 7.49 (1.22 to 13.75) 0.52 (–3.60 to 4.65) 7.84 (1.23 to 14.45)
> 23 195 7.94 (1.42 to 14.45) 5.94 (1.66 to 10.22) 3.19 (–3.68 to 10.05)
p for trend test 0.03 0.005 0.52
Patella lead tertile (µg/g)
< 22 207 Reference Reference Reference
22–33 190 4.14 (–2.19 to 10.46) 2.87 (–1.02 to 7.33) 0.94 (–5.73 to 7.61)
> 33 202 2.69 (–3.68 to 9.06) 3.16 (–1.34 to 7.07) 0.53 (–6.18 to 7.23)
p for trend test 0.45 0.20 0.90
Blood lead tertile (µg/dL)
< 4 240 Reference Reference Reference
4–6 153 1.72 (–4.94 to 8.38) 2.76 (–1.65 to 7.17) –0.11 (–7.09 to 6.87)
> 6 196 –3.54 (–9.74 to 2.66) 1.51 (–2.58 to 5.61) –6.15 (–12.63 to 0.34)
p for trend test 0.32 0.40 0.08
aAdjusted for age (years) and age squared, education (≤ high school, some college, college graduate, or graduate school), 
smoking (never, former, or current and pack-years), BMI (kg/m2), albumin-adjusted serum calcium (mg/dL), and diabetes 
status (yes/no) at baseline, as well as years between ECG tests and QT-prolongation drugs (yes/no) at the time of ECG 
measurement. The measures analysis approach includes participants who did not have a follow-up ECG (see “Materials 
and Methods”).Eum et al.
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adjusted for many known potential confound-
ers, as in any observational study, our results 
could be confounded by unmeasured vari-
ables. Approximately 20% of subjects were 
lost to follow-up, which could introduce a 
potential source of selection bias if attrition 
was associated both with exposure and out-
come. However, subjects not lost to follow-up 
did not have statistically different age-adjusted 
lead levels or QTc intervals from those sub-
jects lost to follow-up (p = 0.80, 0.85, and 
0.22 for difference of levels of tibia, patella, 
and QTc interval, respectively). We also could 
not assess effects among women because all of 
our subjects were men.
Our study is the first longitudinal study 
to examine cumulative lead exposure and sub-
sequent development of cardiac conduction 
disorders, including temporal changes in QTc 
interval and QRSc duration. The results sug-
gest that low-level cumulative exposure to lead 
is associated with future cardiac conductivity 
dysfunction in the ventricular myocardium, as 
reflected in QT interval characteristics, a risk 
factor for sudden death (Chugh et al. 2009). 
These results suggest that people with higher 
bone lead are a susceptible group for cardiac 
dysfunction.
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